Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its fourth quarter and full year 2021 financial results on February 25, 2022, before market open. The company specializes in Red Cell Therapeutics™, focusing on developing innovative cellular medicines for cancer and autoimmune diseases. Importantly, it will not hold a teleconference to discuss the results. Recently, Rubius was recognized as one of the Top Places to Work in Massachusetts and its manufacturing site received accolades in Rhode Island.

CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:
Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com 

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com 

FAQ

When will Rubius Therapeutics report its 2021 financial results?

Rubius Therapeutics will report its fourth quarter and full year 2021 financial results on February 25, 2022, before market open.

Will there be a conference call for Rubius Therapeutics' financial results?

No, Rubius Therapeutics will not host a teleconference in conjunction with its financial results press release.

What is Rubius Therapeutics focused on?

Rubius Therapeutics focuses on developing Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases.

What accolades has Rubius Therapeutics received recently?

Rubius was named among the Top Places to Work in Massachusetts and its manufacturing site was recognized as one of the Best Places to Work in Rhode Island.